Morgan Stanley Boosts Rating On Pfizer, Inc. (PFE) To “Overweight”


Pfizer, Inc. (NYSE:PFE).

On August 2 the company was upgraded to “Outperform” from “Market Perform” in an announcement from BMO Capital. On July 20, 2017 the stock rating was rated “Neutral” by Credit Suisse down from the previous “Outperform” rating.

The company is up by 1.26%% since yesterday’s close of 35.45. Additionally the company recently announced a dividend for shareholders paid on Friday the 1st of September 2017. The dividend payment was $0.320 per share for the quarter or $1.28 annualized. This dividend represents a yield of $3.62. The ex-dividend date was set for Wednesday the 2nd of August 2017.

Shares last traded at $35.90 slightly over the 50 day moving average of $33.78 and just above the 200 day moving average of $33.53. The 50 day moving average went up by +6.266% whereas the 200 day moving average was up $2.36 or +7.047%.

Pfizer Inc. (Pfizer), launched on June 2, 1942, is a research-based global biopharmaceutical company. The Company is involved in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients’ lives, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. As of December 31, 2016, the Company sold its products in over 125 countries..

The most current P/E ratio is 26.258 and the market cap is 213.48B. In the last earnings report the EPS was $1.37 and is estimated to be $2.56 for the current year with 5,947,349,000 shares outstanding. Next quarter’s EPS is forecasted to be $0.56 with next year’s EPS projected to be $2.76.

Traders are feeling more bearish on the company recently if you take a look at the increase in short interest. The firm recorded a rise in short interest of 11.46% between August 15, 2017 and August 31, 2017. Short interest grew 4,633,647 over that timeframe. With short interest at 45,068,122 and short average daily volume at 14,631,410, the short-interest ratio is 3.0 and the percentage of shorted shares was 0.02% on August 31.